Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

21.25 +0.59 (+2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
14 Analysts Have This to Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗
Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a  
Via Benzinga
News headline image
21 Analysts Have This to Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition... 
Via Benzinga
Topics Stocks
News headline image
Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today? ↗
On Wednesday, Annexon Inc (NASDAQ: ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form... 
Via Benzinga
News headline image
Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday? ↗
It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024. 
Via Benzinga
Topics Economy
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced an update on the ongoing review of its marketing application for intravitreal pegcetacoplan for geographic atrophy (GA) secondary to age-related... 
Via Benzinga
News headline image
Apellis Crashes As Likely European Rejection Looms For Eye Drug Syfovre ↗
The treatment, Syfovre, has faced numerous safety concerns in the U.S., where it's approved. 
Via Investor's Business Daily
News headline image
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
Conference call today at 8:30 a.m. ET 
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
News headline image
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
News headline image
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch ↗
BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Buy from Neutral,  
Via Benzinga
News headline image
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration ↗
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. ↗
San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc.... 
Via SBWire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.